Figure 6. CircRHOT1 contributes to breast cancer progression by miR-106a-5p/STAT3 axis. (A–D) The MDA-MB-231 and T47D cells were treated control shRNA, circRHOT1 shRNA, or co-treated with circRHOT1 shRNA and miR-106a-5p inhibitor or pcDNA.1-STAT3. (A, B) The cell viability was measured by MTT assays in the cells. (C, D) The cell apoptosis was measure by flow cytometry analysis in the cells. Data are presented as mean ± SD. Statistic significant differences were indicated: ** P < 0.01.